AviadoBio appoints David Cooper as CMO

Pre-clinical stage gene therapy company AviadoBio has announced the appointment of David Cooper as chief medical officer (CMO).

Dr Cooper worked previously as vice president, clinical development for Dutch company uniQure (Nasdaq: QURE), leading the translation of pre-clinical gene therapy assets to the clinic and executing on multiple clinical programs up to Phase III. This included the pioneering first human dose studies in the USA and European Union for intraparenchymal gene therapy for early-stage Huntington’s disease.

"I have no doubt he will make a tremendous impact as we advance our gene therapies into the clinic"